Study of cadonilimab plus SOX before and after surgery for stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery can help treat stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this combination improves outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach or gastroesophageal junction cancer that is confirmed by biopsy and can be removed with surgery.
- Your cancer is at a certain stage (T3-4a with lymph node involvement or T4b without distant spread) as determined by imaging.
- You are in good enough physical condition to be up and about (ECOG score 0 or 1).
- You have a life expectancy of at least 6 months.
- You must be willing to provide a tissue sample from your tumor before the study starts.
- You are scheduled to have surgery to remove the cancer as part of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
This study tests whether adding cadonilimab (and possibly AK117) to chemotherapy can improve outcomes for people with resectable stomach or stomach–esophagus cancer. It aims to see if this combination works better than chemotherapy alone, while still being safe around surgery.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
This trial tests a new combination of an immunotherapy drug (cadonilimab) plus standard chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
Hear when a new Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.